SCHEMBL394841

SCHEMBL394841

CC(C)(C)N(CC(=O)O)C(=O)OCOC(=O)CC1CCCCC1

nearest known ligand 0.37

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 6/20 0.34
ALDH1A1 P00352 4/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
CTSK P43235 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 1/20 0.32
ATM Q13315 1/20 0.32
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392732 0.99 L3MBTL1 (0.35) LMNAL3MBTL1ALDH1A1SMN1; SMN2CTSK
SCHEMBL392957 0.88 MEN1 (0.44) LMNAL3MBTL1ALDH1A1SMN1; SMN2TDP1
SCHEMBL392735 0.82 SIGMAR1 (0.40) L3MBTL1ALDH1A1SMN1; SMN2CTSKTDP1
SCHEMBL394590 0.82 ADRB2 (0.38) LMNAL3MBTL1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL392995 0.81 SIGMAR1 (0.41) L3MBTL1ALDH1A1SMN1; SMN2CTSKTDP1
SCHEMBL395261 0.81 ADRB2 (0.39) L3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL394383 0.78 ADRB2 (0.36) ALDH1A1MAPTATM
SCHEMBL392561 0.77 RECQL (0.33) ALDH1A1MAPTATMGAA
SCHEMBL393412 0.74 KLK7 (0.44) LMNAL3MBTL1ALDH1A1SMN1; SMN2CTSK
SCHEMBL392739 0.73 PRKCA (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP claimed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO claimed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US claimed
US-8101590-B2 9-aminocarbonylsubstituted derivatives of glycylcyclines WYETH LLC (US) 2012-01-24 US disclosed
EP-1919879-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES Wyeth a Corporation of the State of Delaware (US) 2008-05-14 EP disclosed
WO-2007027599-A1 9-AMINOCARBONYLSUBSTITUTED DERIVATIVES OF GLYCYLCYCLINES WYETH (US) 2007-03-08 WO disclosed
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines WYETH (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049564-A1 9-Aminocarbonylsubstituted derivatives of glycylcyclines Q6ZSR9, GMPS, RPS10 LMNA 2954/4885L3MBTL1 3336/4885ALDH1A1 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.